NeoGenesis Capital
Status
ACTIVE
Global HQ
California, United States
Countries of investment
- United States
Investment stages
- Seed
- Series A
- Series C
Industries
- Biotechnology
- Biology
- Genomics
- Life Sciences
- AI
- Deep Tech
About
NeoGenesis Capital is a United States-based venture firm focused on programmable and synthetic biology. It launched its Fund I in October 2026 with a $33.1M initial close. Their investments are concentrated in the United States, and the fund is built around its relationship with Colossal Biosciences while also looking at early spinouts in the field.
NeoGenesis Capital is a United States-based venture firm focused on programmable and synthetic biology. It launched its Fund I in October 2026 with a $33.1M initial close. Their investments are concentrated in the United States, and the fund is built around its relationship with Colossal Biosciences while also looking at early spinouts in the field.
Investment Thesis
NeoGenesis Capital is a venture firm investing in programmable and synthetic biology, spanning early spinouts through later-stage rounds. Their core thesis is that the ability to engineer living systems will create a new generation of companies, including those at the overlap with superintelligence and advanced AI. What makes NeoGenesis unique is that its Fund I is built around Colossal Biosciences, which has already raised a Series C, giving the firm an anchor portfolio company and a clear lens on the field.
Manager's Experience
Co-founded by Peter H. Diamandis (Co-Founder and Partner, founder of XPRIZE and co-founder of Singularity University) and Yianni Psaltis (Co-Founder and Managing Partner), with Oliver Trevena as Head of Culture. A small founder led team that has publicly named three portfolio companies, Colossal Biosciences, Breaking and Astromech, plus one in stealth. Based in the United States and backs frontier technology companies.
Team
Peter H. Diamandis - Co-Founder and Partner
Yianni Psaltis - Co-Founder and Managing Partner
Oliver Trevena - Head of Culture
Portfolio
Colossal Biosciences
Breaking
Astromech